Publications by authors named "A V Eremeeva"
Unlabelled: . Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here, we present 1-year efficacy and safety data of the SOLAR study.
View Article and Find Full Text PDF[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Zh Nevrol Psikhiatr Im S S Korsakova
April 2024
Objective: To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses.
Material And Methods: The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks, then entered an additional period from weeks 49 to 100, which included three cycles of therapy.
Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID).
BMC Med
February 2024
Article Synopsis
- - The study aimed to explore long-term health outcomes in children and young people post-COVID-19, particularly focusing on post-COVID-19 condition (PCC) and incomplete recovery, comparing these outcomes with those from other non-SARS-CoV-2 infections.
- - Conducted in Moscow, researchers followed two cohorts of pediatric patients with confirmed COVID-19 from two different time periods (Wuhan and Omicron variants) and compared them to a reference group of those with other infections but negative for SARS-CoV-2.
- - Findings revealed that the incidence of PCC was significantly higher in the Wuhan variant group compared to the reference group, while the Omicron variant showed no significant difference in PCC outcomes when compared to the
Process of grain drying is discussed by the authors, which is considered one of the preliminary stages in the technology of biodiesel production. The drying process has a number of disadvantages that affect the quality and cost of biodiesel fuel. The impossibility of uniform heating and maintaining the required temperature with minimal energy costs is considered one of the most important defects that deserve scientific research.
View Article and Find Full Text PDFObjective: To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in comparison with the teriflunomide (TRF). The study of the efficacy and safety of the use of the drug DIV was carried out for 48 weeks of therapy.
Material And Methods: The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS included 338 adult patients with RRMS distributed in a 1:1 ratio into two groups: DIV 500 mg and TRF 14 mg.